Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis

What is the impact of disease-modifying therapy (DMT) management during pregnancy on relapse risk in women with multiple sclerosis (MS)?In this cohort study of 6341 pregnancies, DMT management during pregnancy significantly increased the risk of relapse, particularly in women receiving natalizumab when it was interrupted before or early in pregnancy, or fingolimod. The use of anti-CD20 before pregnancy was the most effective strategy to mitigate this risk.The findings suggest that DMT management during pregnancy can significantly increase relapse rate in women with MS, highlighting the importance of careful therapeutic planning before pregnancy.

Corresponding Author: Antoine Gavoille, MD, Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, 59 boulevard Pinel, F-69677 Bron Cedex, France (antoine.gavoille@chu-lyon.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.